Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Holdings Boosted by Strs Ohio

Strs Ohio boosted its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 18.9% during the 4th quarter, HoldingsChannel reports. The firm owned 25,200 shares of the biotechnology company’s stock after buying an additional 4,000 shares during the quarter. Strs Ohio’s holdings in Arcturus Therapeutics were worth $794,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ARCT. SG Americas Securities LLC purchased a new position in Arcturus Therapeutics during the 3rd quarter worth approximately $1,938,000. Commonwealth Equity Services LLC boosted its stake in shares of Arcturus Therapeutics by 27.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 14,739 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 3,200 shares during the period. Robeco Institutional Asset Management B.V. acquired a new stake in shares of Arcturus Therapeutics during the 3rd quarter valued at $303,000. Stratos Wealth Partners LTD. acquired a new stake in shares of Arcturus Therapeutics during the 3rd quarter valued at $301,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Arcturus Therapeutics by 3.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 94,427 shares of the biotechnology company’s stock valued at $2,413,000 after buying an additional 3,587 shares during the period. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ARCT has been the subject of a number of research reports. Citigroup lifted their target price on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a research note on Friday, March 8th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a research report on Wednesday, March 20th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Arcturus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.33.

Arcturus Therapeutics Stock Performance

Shares of ARCT stock opened at $26.98 on Thursday. The stock’s 50 day simple moving average is $34.18 and its 200 day simple moving average is $29.81. Arcturus Therapeutics Holdings Inc. has a twelve month low of $17.52 and a twelve month high of $43.81. The company has a market capitalization of $726.30 million, a price-to-earnings ratio of -25.94 and a beta of 2.60.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.69) by $1.37. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. The business had revenue of $33.99 million for the quarter, compared to the consensus estimate of $64.14 million. On average, analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.83 EPS for the current fiscal year.

Insider Buying and Selling at Arcturus Therapeutics

In other Arcturus Therapeutics news, COO Pad Chivukula sold 17,435 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $35.02, for a total value of $610,573.70. Following the sale, the chief operating officer now owns 473,448 shares of the company’s stock, valued at approximately $16,580,148.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 13.80% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.